Glaukos (NYSE:GKOS) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Glaukos (NYSE:GKOS) issued its quarterly earnings data on Thursday. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02), Zacks reports. The business had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Glaukos updated its FY 2025 guidance to EPS.

Glaukos Price Performance

Glaukos stock opened at $126.03 on Friday. Glaukos has a twelve month low of $83.90 and a twelve month high of $163.71. The firm has a 50 day moving average price of $152.75 and a 200-day moving average price of $139.25. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Insider Activity

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the sale, the insider now directly owns 72,437 shares in the company, valued at $10,658,380.18. This represents a 4.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Gilbert H. Kliman sold 10,000 shares of the firm’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the sale, the director now owns 32,336 shares in the company, valued at approximately $4,859,454.08. This trade represents a 23.62 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,744 shares of company stock valued at $2,792,151 in the last three months. Company insiders own 6.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Needham & Company LLC boosted their target price on shares of Glaukos from $149.00 to $176.00 and gave the company a “buy” rating in a report on Friday. BTIG Research upped their price objective on shares of Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Stifel Nicolaus upped their price objective on shares of Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. UBS Group assumed coverage on shares of Glaukos in a report on Friday, December 6th. They set a “buy” rating and a $182.00 price objective on the stock. Finally, Citigroup upgraded shares of Glaukos from a “neutral” rating to a “buy” rating and upped their target price for the stock from $132.00 to $162.00 in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $163.25.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.